VTRS Viatrisdata gap · 74% coveragelimited data
Health Care · Pharmaceuticals · close $18.66 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Viatris (VTRS) has a ThetaGrade House Rating of 36/100 (grade D), ranking #88 of 150 in Health Care. Its strongest pillars are valuation (80) and cash flow (75); its weakest is balance sheet (18). Data gap: 4 factors without usable data, so 74% of the method weight is covered. TTM revenue growth is 4.5% and operating margin -0.6%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 74% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 23| Revenue growth YoY (TTM) (22.2%) | 4.5% | 21 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | -3.3% | 27 |
Profitability
weight 18.5% (→20.0%) · 20| Operating margin (10.7%) | -0.6% | 23 |
| 4Q gross-margin change (9.3%) | -1.8% | 16 |
Balance sheet
weight 18.5% (→20.0%) · 18| Net debt / EBITDA (10.7%) | 4.60× | 11 |
| Current ratio (5.3%) | 1.58 | 30 |
| Interest coverage (4.0%) | -0.19× | 21 |
Cash flow
weight 12.33% (→13.3%) · 75| FCF margin (6.7%) | 13.6% | 54 |
| FCF yield (6.7%) | 9.0% | 96 |
Valuation
weight 12.33% (→13.3%) · 80| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 2.31× | 80 |
Technicals (EOD)
| RSI(14) | 69.1 |
| EMA 9 / 21 | 17.83 / 17.57 |
| 200-day SMA | 15.60 |
| Volume vs 20d avg | 1.00× |
| 20-day return | 8.9% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: net debt/EBITDA above 4×
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: OperatingIncomeLoss · Interest expense: InterestExpense · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like VTRS's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is VTRS's House Rating?
- VTRS scores 36 out of 100 (grade D) as of 2026-10-16, ranking #88 of 150 Health Care stocks we cover.
- What do analysts say about VTRS?
- We do not have enough analyst-sentiment data to score this stock.
- When does VTRS report earnings next?
- VTRS's next earnings report is estimated for about 2026-11-05 (window 2026-11-02 to 2026-11-08), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is VTRS a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology